SEC Form 4 · accession 0001171843-16-007036
Protara Therapeutics, Inc. · TARA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy P Noyes
Officer — President and CEO · Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 5, 2016 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001359931
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 4, 2016 | M | 5,000 | $1.91 | A | 5,000 | D | |
| Common StockF2 | Jan 4, 2016 | S | 5,000 | $13.88 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $1.91 | Jan 4, 2016 | M | 5,000 | D | — | Apr 19, 2016 | Common Stock, $0.001 par value | 5,000 | 58,742 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2015.
- F2The selling price of $13.88 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $13.38 to $14.71.
- F3The option was granted on April 19, 2006. All shares underlying the option have vested.